Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspira Women's Health Inc.awh · Entity 7871 | Chief Financial Officer | March 31, 2022 | April 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspira Women's Health Inc.
Report date March 31, 2022 · Filed April 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2032-03-31 | Direct | 150,000 |
Reported balance
After 2022-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-31 · Grant · Acquired 150,000 · Balance 150,000 F1: The option vests in four equal annual installments beginning on March 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal annual installments beginning on March 31, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2022 Filed Apr 4, 2022 22:16 UTC | Aspira Women's Health Inc. awh · Entity 7871 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001725914-22-000002 · primary_doc.xml · derivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-03-31 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 31, 2023. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 21:57 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantEMPLOYEE STOCK OPTION (RIGHT TO BUY) · Derivative | 150,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001725914-21-000001 · primary_doc.xml · derivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2031-03-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 19, 2022. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 01:04 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantEMPLOYEE STOCK OPTION (RIGHT TO BUY) · Derivative | 50,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001725914-20-000003 · primary_doc.xml · derivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-08 F1 · derivative.exercise_date: An option to purchase 100,000 shares of common stock was granted to the reporting person on 1/8/19, subject to the satisfaction of certain performance conditions. On 6/1/20, a portion of the performance conditions were deemed to have been met, resulting in 50,000 shares earned. The remaining option to purchase 50,000 shares was canceled. Half of the achieved portion of the option grant is immediately exercisable and the remaining 50% will vest on 3/31/21. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 21:27 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001725914-20-000002 · primary_doc.xml · derivative · entry 1 Beechey Robert Harry · CIK 0001725914 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 19, 2021. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 16:02 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseCommon Stock, par value $0.001 per share | 5,000 | $0.71 | $3,541.50 |
DisclosureSEC source: 0001725914-19-000003 · primary_doc.xml · nonDerivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Read SEC document |
| May 17, 2019 Filed May 17, 2019 16:26 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseCommon Stock, par value $0.001 per share | 5,000 | $1.26 | $6,292.00 |
DisclosureSEC source: 0001725914-19-000002 · primary_doc.xml · nonDerivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,000 Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 23:53 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantEMPLOYEE STOCK OPTION (RIGHT TO BUY) · Derivative | 150,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001725914-19-000001 · primary_doc.xml · derivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-03-26 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 26, 2020. Read SEC document |
| December 06, 2018 Filed Dec 6, 2018 21:23 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseCommon Stock, par value $0.001 per share | 25,000 | $0.57 | $14,250.00 |
DisclosureSEC source: 0001725914-18-000004 · primary_doc.xml · nonDerivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · price: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.567 to $0.572 per share. The reporting person undertakes to provide to Vermillion, any security holder of Vermillion or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| August 23, 2018 Filed Aug 23, 2018 20:10 UTC | Aspira Women's Health Inc. vrml · Entity 7871 | PurchaseCommon Stock, par value $0.001 per share | 75,000 | $0.61 | $45,750.00 |
DisclosureSEC source: 0001725914-18-000003 · primary_doc.xml · nonDerivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 F1 · price: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.609 to $0.630 per share. The reporting person undertakes to provide to Vermillion, any security holder of Vermillion or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:11 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseCommon Stock, par value $0.001 per share | 100,000 | $0.52 | $52,000.00 |
DisclosureSEC source: 0001725914-18-000002 · primary_doc.xml · nonDerivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · price: The purchase reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.515713 to $0.519931 per share. The reporting person undertakes to provide to Vermillion, any security holder of Vermillion or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 21:05 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001725914-18-000001 · primary_doc.xml · derivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-04-13 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on April 13, 2019. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:29 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | GrantEmployee stock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001725914-17-000002 · primary_doc.xml · derivative · entry 1 Beechey Robert Harry · CIK 0001725914 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 18, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.